Codexis Inc (CDXS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $127.13M
Last updated: Nov 17, 2026 at 11:04 AM ET
Codexis Inc (CDXS) Stock Forecast
Analysts expect Codexis (CDXS) to earn -$0.43 per share in the fiscal year ending Dec 31, 2026, on revenue of $73.88M. Of 8 analysts, 6 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 2.13, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 75% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 12.5% |
| Buy | 5 | 62.5% |
| Hold | 2 | 25.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 18.7%.
- Fiscal year ending Dec 31, 2026
- -$0.43
- EPS consensus, revenue $73.88M
- Fiscal year ending Dec 31, 2027
- -$0.32
- EPS consensus, revenue $87.72M
- Next report
- Mar 9, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.43 | -$0.43 to -$0.42 | 2 | $73.88M | $72.46M to $75.80M | 8 |
| Dec 31, 2027 | -$0.32 | -$0.32 to -$0.32 | 2 | $87.72M | $81.00M to $108.88M | 7 |
Quarterly Estimates
The EPS consensus rises from -$0.09 for the quarter ending Dec 31, 2026 to -$0.08 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.09 | -$0.18 to -$0.05 | 9 | $25.11M | $22.39M to $27.72M | 10 |
| Mar 31, 2027 | -$0.08 | -$0.10 to -$0.06 | 2 | $18.31M | $16.20M to $21.97M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.36.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.43 | -$0.42 | -$0.42 | -$0.36 | -$0.36 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.32 | -$0.32 | -$0.32 | -$0.37 | -$0.37 | N/A |
| Quarter ending Mar 31, 2027 | -$0.08 | -$0.10 | -$0.10 | -$0.12 | -$0.12 | N/A |
Frequently Asked Questions About CDXS
What is the CDXS stock forecast?
Consensus analyst estimates put Codexis's EPS at -$0.43 for the fiscal year ending Dec 31, 2026, on revenue of $73.88M. The consensus rating from 8 analysts is Buy.
How do analysts rate CDXS stock?
Of 8 analysts covering Codexis, 1 rates it Strong Buy, 5 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CDXS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.43, with estimates from -$0.43 to -$0.42 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.32, with estimates from -$0.32 to -$0.32 from 2 analysts.
What revenue do analysts expect from Codexis next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $73.88M, with estimates from $72.46M to $75.80M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $87.72M, with estimates from $81.00M to $108.88M.
How many analysts cover CDXS?
8 analysts rate Codexis stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CDXS pages: Overview, Earnings, Forecast, Financials, Competitors